Halozyme Therapeutics Inc

Financials

Flujo de caja de las actividades operativas 55.45 M299.44 M240.11 M388.57 M479.06 M651.56 M 651.56 M Flujo de caja de las actividades de inversión 78.35 M-406.29 M-487 M-96.91 M-262.72 M-545.81 M -545.81 M Flujo de caja de las actividades financieras -106.28 M77.86 M362.37 M-407.99 M-218.86 M-85.17 M -85.17 M Flujo de caja libre 52.95 M297.98 M235.3 M373.28 M468.37 M644.59 M 644.59 M

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

HALO

Financials

Halozyme Therapeutics Inc

Noticias

Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?

TD Cowen reitera calificación de Compra en Halozyme por crecimiento de regalías

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

La directora ejecutiva de Halozyme Therapeutics, Helen Torley, vende acciones por 634.981 dólares

Halozyme licencia tecnología Hypercon a Vertex por 15 millones de dólares

Leerink reitera calificación de Halozyme tras acuerdo con Vertex

Leaderboard Trimmed, But Cloudflare, Caterpillar Among 5 Stocks To Watch

JNJ: Success In Multiple Myeloma Underpins $25B In Growth By 2030 (NYSE:JNJ)

La directora ejecutiva de Halozyme Therapeutics vende acciones por 2,59 millones de dólares

Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?

Halozyme nombra a David Ramsay como CFO interino

Halozyme names David Ramsay as interim CFO